Clinical Trial Search

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Best Response — 20; 3; 3 Participants

Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…

Primary: Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I) — 400; 400 mg

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients

Primary: Participants With a Clinical Response — 0 Participants

Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 0 participants

Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability

Primary: Proportion of Subjects With a Complete Response Rate (CR) at 1 Year of Therapy — 0.26 proportion of participants

Primary: Overall Survival — 34 Participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Arm A: Percentage of Complete Responses — 46 percentage of participants

Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants

Primary: Phase I: Maximum Tolerated Dose (MTD) — NA mg

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Response Based on Overall Response Rate — 17; 11; 28; 6 Participants

Primary: Number of Patients With Complete Response (CR) — 11 Participants

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…

Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants

Primary: Complete Response Rate — 10 percentage of participants

Primary: Overall Response Rate (ORR) — 15; 30 participants